Answers are grounded in this paper and cite their sources.
In this preliminary trial, ozanimod at a daily dose of 1 mg resulted in a slightly higher rate of clinical remission of ulcerative colitis than placebo. The trial was not large enough or of sufficiently long duration to establish clinical efficacy or assess safety. (Funded by Receptos; TOUCHSTONE ClinicalTrials.gov number, NCT01647516.).
No takes yet. Share an insight, caveat, or question.
Sandborn et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: